Arno Therapeutics, Inc.
ARNI · OTC
9/30/2016 | 6/30/2016 | 3/31/2016 | 12/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.03 | 0.02 | -0.00 |
| FCF Yield | -5.43% | -12.95% | -18.02% | -30.43% |
| EV / EBITDA | -4.91 | -5.62 | -4.27 | -3.37 |
| Quality | ||||
| ROIC | -268.04% | 485.80% | -173.75% | 152.85% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.30 | 0.78 | 0.72 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 32.13% | 36.72% | -23.89% | 4.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.44 | 0.95 | -0.75 |
| Interest Coverage | -10,426.48 | -13,242.14 | -194.61 | -98.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |